In skin squamous cell carcinoma (SCC), CRISPR/Cas9-mediated IGF2BP1 knockout reduces the levels of IGF2BP1-stabilized mRNAs, including IGF2, CD44, Gli1, and Myc, subsequently leading to the inhibition of skin SCC cell survival and proliferation (163). This evidence concerns the gene IGF2BP1 and skin squamous cell carcinoma.